Actemra IV (tocilizumab) / JW Pharma, Roche  >>  Phase 3
Welcome,         Profile    Billing    Logout  

43 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Actemra IV (tocilizumab) / Roche, JW Pharma
ACTRN12614000266662: Use of Tocilizumab (TCZ) to prevent acute graft versus host disease (GVHD) randomized trial

Recruiting
3
110
 
Royal Brisbane and Women's Hospital, National Health & Medical Research Council
Acute graft versus host disease (GVHD) post HLA-matched allogeneic haematopoietic progenitor cell transplantation (HPCT)
 
 
2014-003529-16: Stratification of biologic Therapies for Rheumatoid Arthritis by Pathobiology

Ongoing
3
219
Europe
MabThera, RoActmera, Enbrel, Concentrate for solution for infusion, Solution for injection, Solution for injection in pre-filled pen, MabThera, RoActmera, Enbrel
Joint Research & Development Office (QMUL), Medical Research Council, Arthritis Research UK
Rheumatoid Arthritis, Rheumatoid Arthritis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2015-005389-51: Safety and Efficacy of tocilizuMAb versus placebo in Polymyalgia rHeumatica with glucocORticoid dEpendence SEMAPHORE

Ongoing
3
100
Europe
RoActemra, Concentrate and solvent for solution for infusion, Tocilizumab
CHRU DE BREST, Laboratoire CHUGAI
Polymyalgia rHeumatica, Inflammatory disease in the elderly, Diseases [C] - Immune System Diseases [C20]
 
 
2017-004079-30: Stratification of biologic Therapies for Rheumatoid Arthritis by Pathobiology

Ongoing
3
219
Europe
MabThera, RoActmera, Enbrel, Concentrate for solution for infusion, Solution for injection, Solution for injection in pre-filled pen, MabThera, RoActmera, Enbrel
Joint Research & Development Office (QMUL), AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITà DI NOVARA, Medical Research Council, Arthritis Research UK, Queen Mary University of London (QMUL)
Rheumatoid Arthritis, Rheumatoid Arthritis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2014-003484-38: Evaluation de l'efficacité du Tocilizumab dans l'arthrose digitale invalidante et réfractaire aux traitements usuels

Not yet recruiting
3
90
Europe
RoActemra, EMEA/H/C/000955, Concentrate for solution for injection, Roche Registration Limited
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
Patients atteints d'arthrose digitale (IPD et IPP) selon les critères de l'ACR symptomatique (douleur au moins 1 jour sur 2 dans le dernier mois) évoluant depuis plus de 3 mois, patients souffrant d'une arthrose digitale invalidante et réfractaire aux traitements usuels, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2018-002826-22: Comparaison entre le Méthotrexate et le Tocilizumab pour le traitement de l'artérite à cellules géantes

Not yet recruiting
3
200
Europe
Solution for injection, Solution for injection in pre-filled syringe, METOJECT, RoActemra
CHU Dijon Bourgogne
Artérite à cellules géantes, Maladie de Horton, Diseases [C] - Immune System Diseases [C20]
 
 
2020-001903-17: Effects of Tocilizumab and its combination with Vitamin D to treat the increased defensive response in COVID-19 Efecto de Tocilizumab y su combinación con Vitamina D para el tratamiento de la respuesta defensiva aumentada al COVID-19

Ongoing
3
120
Europe
Tocilizumab (Actemra/RoActemra)™ , Roche, VITAMINE D3 BON 200 000 U.I./1 ml, solution injectable, L04AC07, A11CC05, Solution for injection/infusion, Solution for injection, Tocilizumab (Actemra/RoActemra)™ , Roche, VITAMINE D3 BON 200 000 U.I./1 ml, solution injectable IM en ampoule, boîte de 1 ampoule
HOSPITAL UNIVERISTARIO DE MOSTOLES, SERMAS
COVID INFECTION IS A MILD FLU LIKE CONDITION WITH MILD FEVER, DRY COUGH, WIDESPREAD TENDERNESS AND OLFACTORY DISFUNCTION FOLLOWED BY A SERIOUS SITUATION IN SOME 20% OF PATIENTS WITH OVERT FEVER, MALAISE, CHILLS AND DYSPNEA DUE TO HYPERIMMUNE RESPONSE. OXYGEN IS LIKELY TO BE GIVEN IN ABOUT 70% OF PATIENTS AND MORTALITY RATE VARIES FROM 10 TO 40% OF SEVERE CASES. LA INFECCION POR COVID ES UNA ESPECIE DE GRIPE CON FEBRICULA, TOS SECA,DOLORES DIFUSOS Y ALTERACIÓN OLFATIVA SEGUIDAD DE UN CUADRO GRAVE 820% DE PACIENTES) CON FIEBRE FRANCA, MALESTAR GENERAL, ESCALOFRIOS Y DISNEA DEBIDA A UNA HIPERRESPUESTA INMUNE.SERA NECESARIO OXIGENOTERAPIA EN UN 70% DE PACIENTES Y LA MORTALIDAD OSCILA ENTRE EL 10 Y EL 40% DE LOS CASOS GRAVES., CORONAVIRUS IS A FLU LIKE STATE WITH MILD FEVER , COUGH AND MILD PAIN IN LIMBS THAT LATER ON SHOWS HIGH FEVER, PAIN AND DIFFICULTY TO BREATHE WITH OXYGEN NEEDS DUE TO INCREASED DEFENSIVE RESPONSE. EL CORONAVIRUS ES UNA ESPECIE DE GRIPE CON FIEBRE BAJA, TOS Y MOLESTIAS QUE DESPUES DA FIEBRE ALTA, DOLOR Y DIFICULTAD PARA RESPIRAR CON NECESIDAD DE OXIGENO POR UNA RESPUESTA DEFENSIVA EXAGERADA, Diseases [C] - Virus Diseases [C02]
 
 
2020-001707-16: PHASE III RANDOMIZED, UNICENTRIC OPEN, CONTROLLED CLINICAL TRIAL TO DEMONSTRATE THE EFFECTIVENESS OF TOCILIZUMAB AGAINST SYSTEMIC CORTICOTHERAPY IN PATIENTS ENTERED BY COVID-19 WITH BILATERAL PNEUMONIA AND BAD EVOLUTION ENSAYO CLÍNICO ALEATORIZADO, UNICENTRICO, ABIERTO, CONTROLADO, EN FASE III, PARA DEMOSTRAR LA EFECTIVIDAD DE TOCILIZUMAB FRENTE A CORTICOTERAPIA SISTÉMICA EN PACIENTES INGRESADOS POR COVID-19 CON NEUMONÍA BILATERAL Y MALA EVOLUCIÓN

Ongoing
3
60
Europe
tocilizumab, Metilprednisolona, Concentrate for solution for infusion, Solution for injection/infusion, Roactemra, Urbason
IIS BIODONOSTIA, IIS BIODONOSTIA
bilateral SARS-CoV-2 pneumonia with poor clinical course neumonía bilateral por SARS- CoV-2 con mala evolución clínica, bilateral SARS-CoV-2 pneumonia with poor clinical course neumonía bilateral por SARS- CoV-2 con mala evolución clínica, Diseases [C] - Virus Diseases [C02]
 
 
EMPACTA, NCT04372186: A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia

Checkmark Efficacy and safety data from EMPACTA trial in patients with COVID-19 Pneumonia
Sep 2020 - Sep 2020: Efficacy and safety data from EMPACTA trial in patients with COVID-19 Pneumonia
Completed
3
377
US, RoW
Placebo, Tocilizumab
Genentech, Inc.
COVID-19 Pneumonia
08/20
09/20
TRONCHER, NCT04361032: Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia

Not yet recruiting
3
260
RoW
Tocilizumab Injection, ROACTEMRA, Deferoxamine, DESFERAL
Abderrahmane Mami Hospital, Eshmoun Clinical Research Centre, Datametrix
COVID19, Intensive Care Unit
09/20
10/20
2016-000312-15: Treatment tapering in oligoarticular or rheumatoid factor negative polyarticular Juvenile Idiopathic Arthritis with inactive disease on biologic therapy Décroissance thérapeutique dans l'arthrite juvénile idiopathique oligoarticulaire ou polyarticulaire sans facteur rhumatoïde en maladie inactive sous biothérapie.

Not yet recruiting
3
230
Europe
ENBREL, HUMIRA, ROACTEMRA, ORENCIA, Cutaneous solution, Solution for injection, ENBREL, HUMIRA, ROACTEMRA, ORENCIA
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), DGOS
Patients with oligoarticular onset or rheumatoid factor negative polyarticular JIA followed in tertiary care center for paediatric rheumatology.
 
 
2018-002202-31: A Phase 3 study to compare BAT1806 with RoActemra in patients with Rheumatoid Arthritis

Not yet recruiting
3
621
Europe
RoActerma, BAT1806, Infusion, RoActemra
Bio-Thera Solutions, Ltd., Bio-Thera Solutions, Ltd.
Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate, Rheumatoid Arthritis, Diseases [C] - Immune System Diseases [C20]
 
 
2020-005291-35: A multicenter randomized trial to evaluate the efficacy of tocilizumab in patients with severe Coronavirus Disease 2019 (Covid-19) pneumonia failing glucocorticoids. Studio multicentrico randomizzato per valutare l'efficacia di tocilizumab in pazienti con polmonite severa da Coronavirus 2019 (Covid-19) che falliscono la terapia con glucocorticoidi.

Ongoing
3
640
Europe
tocilizumab, [DB06273], Concentrate for solution for infusion
AOU POLICLINICO DI MODENA, Regione Emilia Romagna, Fondazione Cassa di Risparmio di Modena
polmonite severa da coronavirus 2019 severe Coronavirus Disease 2019, polmonite severa da coronavirus 2019 severe Coronavirus Disease 2019, Diseases [C] - Virus Diseases [C02]
 
 
NCT04693026: Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients

Recruiting
3
150
RoW
Remdesivir, Ninavir, Baricitinib, Tocilizumab
M Abdur Rahim Medical College and Hospital, First affiliated Hospital Xi'an Jiaoting University
Covid19, Covid-19 ARDS
02/21
03/21
2020-002275-34: A controlled study on the safety and efficacy of the combination remdesivir plus tocilizumab compared with individual use of these drugs for treatment of severe COVID-19 pneumonia in hospitalized patients Un estudio controlado sobre la seguridad y eficacia de la combinación remdesivir más tocilizumab en comparación con el uso individual de estos fármacos para el tratamiento de la neumonía grave por COVID-19 en pacientes hospitalizados.

Not yet recruiting
3
800
Europe
Actemra, Remdesivir, RO4877533/F03-01, RO7286260/F01, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Actemra®/ RoActemra®, Veklury®
F. Hoffman-La Roche Ltd., F. Hoffmann-La Roche Ltd.
Severe coronavirus disease 2019 (COVID-19) pneumonia Neumonía grave por COVID-19, Severe lower respiratory tract infection caused by a new type of coronavirus. Infección grave del tracto respiratorio inferior causada por un nuevo tipo de coronavirus., Diseases [C] - Virus Diseases [C02]
 
 
ChiCTR2300067652: A Phase III clinical study to compare the safety and efficacy of LZM008 injection and ACTEMRA in patients with moderate to severe active rheumatoid arthritis (RA)

Completed
3
640
 
LZM008, 8 mg/kg, administrated once every 4 weeks and in combination with methotrexate (7.5-25mg/week) ;Tocilizumab Injection (ACTEMRA?), 8 mg/kg, administrated once every 4 weeks and in combination with methotrexate (7.5-25mg/week)
Huashan Hospital, Fudan University / Peking University, Reople’s Hospital; Livzon Mabpharm Inc., Livzon Mabpharm Inc.
Moderate to severe active rheumatoid arthritis
 
 
NCT04423042: Tocilizumab in Coronavirus-19 Positive Patients

Not yet recruiting
3
30
NA
Tocilizumab, Actemra
University of Calgary
Covid19, COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2, Coronavirus, Inflammation
06/21
06/21
2020-002039-31: Use of Tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease

Not yet recruiting
3
90
Europe
RoActemra, Infusion, RoActemra
Turku University Hospitla
COVID-19 / new coronavirus disease, new coronavirus disease (COVID-19), Diseases [C] - Virus Diseases [C02]
 
 
NCT05002517: Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab

Active, not recruiting
3
60
Europe
Tociliziumab group, Methylprednisolone group
Asociacion Instituto Biodonostia
COVID-19 Pneumonia
07/21
10/21
NCT06048224: Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis

Completed
3
669
RoW
HS628+MTX, Actemra +MTX
Zhejiang Hisun Pharmaceutical Co. Ltd.
Moderate to Severe Active Rheumatoid Arthritis
09/21
01/22
ARCHITECTS, NCT04412772: Trial of Tocilizumab for Treatment of Severe COVID-19:

Recruiting
3
300
US
Tocilizumab, Actemra, Placebo
Queen's Medical Centre
COVID-19
12/21
12/21
NCT04000698: Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias

Recruiting
3
25
RoW
Preparative regimen
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Refractory Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia
07/22
12/22
2022-001066-36: Effects of intravenous infusions of either CT-P47 or RoActemra, as co-administered with methotrexate, in patients with active rheumatoid arthritis Ocena wpływu leczenia CT-P47 lub RoActemrą, podawanych we wlewach dożylnych, u pacjentów z aktywnym reumatoidalnym zapaleniem stawów leczonych metotreksatem

Not yet recruiting
3
448
Europe
RoActemra 20 mg/mL concentrate for solution for infusion., CT-P47, Concentrate for solution for infusion, RoActemra 20 mg/mL concentrate for solution for infusion.
CELLTRION, Inc., CELLTRION, Inc.
Moderate to severe active rheumatoid arthritis (RA) diagnosed according to the 2010 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) classification criteria (Aletaha et al., 2010) for at least 24 weeks, who have inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs)., moderate to severe active rheumatoid arthritis (RA), Diseases [C] - Musculoskeletal Diseases [C05]
 
 
INFLAMMACOV, NCT04424056 / 2020-001754-21: A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease

Not yet recruiting
3
216
Europe
Anakinra +/- Ruxolitinib (stages 2b/3), Anakinra and Ruxolitinib (Advanced stage 3), Tocilizumab +/- ruxolitinib (stages 2b/3), Tocilizumab and Ruxolitinib (Advanced stage 3), Standard of care
Assistance Publique Hopitaux De Marseille
Covid19
09/22
11/22
NCT05489224: A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis

Not yet recruiting
3
448
NA
CT-P47, EU-approved RoActemra
Celltrion
Rheumatoid Arthritis
08/23
12/23
NCT05346666: Possible Immuno-Modulatory Effect of Tocilizumab in Patients With Refractory Status Epilepticus.

Recruiting
3
50
RoW
Tocilizumab Prefilled Syringe [Actemra]. propofole, phenobarbital, midazolam
Damanhour University, Principal Investigator Sahar El-Haggar, Prof Clinical pharmacy Department- Tanta University, Principal Investigator Mohanad Omar Ahmed, Msc Pharmacy Practice Department- Horus University, Principal Investigator Sahar Hegazy, Prof Clinical pharmacy Department- Tanta University
Epilepsy
09/23
10/23
RECOVERY, NCT04381936 / 2020-001113-21: Randomised Evaluation of COVID-19 Therapy

Checkmark Efficacy and safety data from RECOVERY trial in COVID-19
Jun 2021 - Jun 2021: Efficacy and safety data from RECOVERY trial in COVID-19
Recruiting
3
70000
Europe, RoW
Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine, Azithromycin, Convalescent plasma, Tocilizumab, Immunoglobulin, Synthetic neutralising antibodies, REGEN-COV, casirivimab and imdevimab, Aspirin, Colchicine, Baricitinib, Anakinra, Dimethyl fumarate, High Dose Corticosteroid, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid, nirmatrelvir/ritonavir, Baloxavir Marboxil, Xofluza, Oseltamivir, Tamiflu, Low-dose corticosteroids: Dexamethasone
University of Oxford, UK Research and Innovation, National Institute for Health Research, United Kingdom, Wellcome, Bill and Melinda Gates Foundation, Department for International Development, United Kingdom, Health Data Research UK, Medical Research Council Population Health Research Unit, NIHR Clinical Trials Unit Support Funding, NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Flu Lab
Severe Acute Respiratory Syndrome
06/26
06/36
NINTOC-TU, NCT06297096: Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease

Not yet recruiting
3
86
Europe
Tocilizumab, Nintedanib, Standard therapy, mycophenolate mofetil, methotrexate
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland, Medical Research Agency, Poland
Systemic Sclerosis, Interstitial Lung Disease
12/27
03/28
IRIS-sICAS, NCT06447701: Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis

Not yet recruiting
3
486
NA
Tocilizumab, NaCl 0.9% 100ml
Zhujiang Hospital, Shenzhen Second People's Hospital, Central People's Hospital of Zhanjiang, Shantou Central Hospital, Eighth Affiliated Hospital, Sun Yat-sen University, Guangzhou First People's Hospital, Peking University Shenzhen Hospital, Guangdong Provincial People's Hospital
Brain Diseases, Ischemic Stroke, Ischemia, Stroke, Cerebral Infarction, Atherosclerosis of Artery, Atheroscleroses, Intracranial
12/25
06/29
STARGLO, NCT04408638 / 2020-001021-31: A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Calendar Jan 2024 - Dec 2024: NME submission in US in combination with chemotherapy for 2L DLBCL
Calendar Jan 2023 - Dec 2024: Data readout from STARGLO trial in combination with gemcitabine and oxaliplatin for r/r DLBCL
Calendar Jan 2023 - Dec 2024: Data readout from STARGLO trial in combination with gemcitabine and oxaliplatin for r/r DLBCL
Feb 2023 - Dec 2023: Data readout from STARGLO trial in combination with gemcitabine and oxaliplatin for 2L+ DLBCL
Active, not recruiting
3
270
Europe, US, RoW
Obinutuzumab, Glofitamab, Rituxumab, Tocilizumab, Gemcitabine, Oxaliplatin
Hoffmann-La Roche
Diffuse Large B-cell Lymphoma
04/25
04/25
SUNMO, NCT05171647: A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Calendar Jan 2023 - Dec 2024: Data from SUNMO trial in combination with polivy for 2L+ DLBCL
Active, not recruiting
3
222
Canada, Japan, US, RoW
Mosunetuzumab, Polatuzumab vedotin, Tocilizumab, Rituximab, Gemcitabine, Oxaliplatin
Hoffmann-La Roche
Non-Hodgkin Lymphoma
02/25
02/27
INTERCEPT, NCT04561986: TocIlizumab in Chronic Antibody-mediated Rejection in Kidney Transplant Recipients

Recruiting
3
50
Europe
Tocilizumab, RoActemra
Vastra Gotaland Region, Karolinska University Hospital, Uppsala University Hospital, Skane University Hospital, The Swedish Research Council
Antibody-mediated Rejection
 
 
METOGiA, NCT03892785: MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial

Active, not recruiting
3
230
Europe
Prednisone treatment, Tocilizumab treatment, Methotrexate treatment, Questionnaires, Blood samples
Centre Hospitalier Universitaire Dijon
Giant Cell Arteritis
01/26
03/27
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
GLOBRYTE, NCT06084936: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Recruiting
3
182
Europe, Canada, US, RoW
Obinutuzumab, Glofitamab, Rituximab, Bendamustine, Lenalidomide, Tocilizumab
Hoffmann-La Roche
Lymphoma
02/26
12/26
PALETTE, NCT06381661: Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Bayesian Basket Trial

Not yet recruiting
3
2000
NA
Tocilizumab, Baricitinib, Anakinra, Hydrocortisone, Hydrocortisone and fludrocortisone, Heparin, Low molecular weight heparin, Recombinant humanThrombomodulin( rhTM), Sivelestat, Fresh frozen plasma, Usual care
Assistance Publique - Hôpitaux de Paris
Sepsis
05/29
04/32
RA-PROPR, NCT04692493: RA-PRO PRAGMATIC TRIAL

Recruiting
3
924
Canada, US
targeted synthetic DMARD class, non-TNFi-biologic class
University of Alabama at Birmingham, Patient-Centered Outcomes Research Institute
Rheumatoid Arthritis
09/26
12/28
NCT05609630: Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

Recruiting
3
90
Europe, Japan, US, RoW
Upadacitinib, RINVOQ, ABT-494, Tocilizumab
AbbVie
Juvenile Idiopathic Arthritis
02/27
06/29
MAGICA, NCT06037460: TocilizuMab discontinuAtion in GIant Cell Arteritis

Recruiting
3
120
Europe
Tocilizumab treatment, questionnaires, Blood samples, 18FDG PET scan
Centre Hospitalier Universitaire Dijon
Giant Cell Arteritis
12/27
11/28
NCT05963048: Rituxmab Versus IL-6 in Treating ILD

Completed
2/3
60
RoW
Rituximab, Rituxan, IL6 inhibitor, Actemra
Assiut University
Interstitial Lung Disease, Scleroderma
12/22
06/23
IRIS, NCT06238024: Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment

Completed
2/3
108
RoW
Tocilizumab, NaCl 0.9% 100ml
Suzhou Municipal Hospital of Anhui Province, Xuanwu Hospital, Beijing
Interleukin-6, Ischemic Stroke, Endovascular Treatment
06/24
09/24
TOMATO, NCT06452537: Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

Recruiting
2/3
102
RoW
Tocilizumab, ACTEMRA®, Prednisone
Tianjin Medical University General Hospital
Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
01/26
07/26
tMG-E, NCT05716035: Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis

Recruiting
2/3
64
RoW
Tocilizumab Injection
Tang-Du Hospital
Myasthenia Gravis, Generalized
07/24
12/24

Download Options